Alphamab Oncology 2019 SR
The report highlights Alphamab Oncology's commitment to developing innovative oncology drugs, specifically bispecific antibodies. In 2019, the company was listed on the Hong Kong Stock Exchange and achieved significant R&D milestones, including phase II clinical trials for its lead candidate KN046. The report details the establishment of a comprehensive quality control system and a new wastewater treatment station to achieve zero emissions. It also emphasizes a talent-oriented philosophy, reporting a 100% employee training participation rate and various employee engagement initiatives.
Company: Alphamab Oncology
Sector: Manufacturing
Country: China
Year: 2019
Type: SR
Pages: 38
Back to company
Alphamab Oncology
ESG Report
The report highlights Alphamab Oncology's commitment to developing innovative oncology drugs, specifically bispecific antibodies. In 2019, the company was listed on the Hong Kong Stock Exchange and achieved significant R&D milestones, including phase II clinical trials for its lead candidate KN046. The report details the establishment of a comprehensive quality control system and a new wastewater treatment station to achieve zero emissions. It also emphasizes a talent-oriented philosophy, reporting a 100% employee training participation rate and various employee engagement initiatives.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Jan 1, 2019 - Dec 31, 2019
Fiscal Year
2019
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Workplace Fatalities
Employees